Sarah  Goldberg, MD, PH

Sarah Goldberg, MD, PH

Yale Cancer Center/Smilow Cancer Hospital

Associate Professor of Internal Medicine (Medical Oncology); Associate Director, Medical Oncology-Hematology Program; Research Director, Center for Thoracic Cancers; Chief, Thoracic Oncology

Expertise: Lung CancerLung CancerMedical OncologyMedical Oncology

Dr. Sarah Goldberg is an Associate Professor of Medicine in the section of Medical Oncology at the Yale School of Medicine. As a thoracic oncologist she cares for patients with cancers of the chest including lung cancer, mesothelioma and thymoma. She is the Division Chief of Thoracic Oncology, the Research Director for the Center for Thoracic Cancers, and the Associate Program Director for the Medical Oncology-Hematology Fellowship Program at Yale.  She received her medical degree from Mount Sinai School of Medicine and completed a Masters in Public Health degree from the Harvard School of Public Health. She conducts clinical and translational research on lung cancer with a focus on investigating biomarkers and novel treatment strategies in non-small cell lung cancer. Her specific research interests include EGFR mutation positive lung cancer, immunotherapeutics for lung cancer, and brain metastases. 

Education & Training:
Fellow-Dana-Farber Cancer Institute, Massachusetts General Hospital (2012)
Resident-Massachusetts General Hospital (2009)
MD-Mount Sinai School of Medicine (2006)
MPH-Harvard School of Public Health

No Clipping

No Research/Citations

Why a Targeted Therapy Is Better Than Immunotherapy For Some Patients With Inoperable Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC), with an epidermal growth factor receptor (EGFR) mutation, tends not to respond well to immunotherapy treatments, including durvalumab. However, Yale Cancer Center (YCC) researchers recently reported in the Journal of Thoracic Oncology that the targeted therapy osimertinib, when administered after chemotherapy and radiation, is associated with significantly improved progression-free survival (living without the cancer worsening).
31-Jan-2024 07:05:14 PM EST

New immunotherapy treatment brings hope to patients with advanced non-small cell lung cancer

Although immunotherapies have shown promise in treating non-small cell lung cancer (NSCLC), many patients still do not respond well, and those who do may eventually develop resistance.
08-Sep-2023 01:05:13 PM EDT

No Quotes

Available for logged-in users onlyLogin HereorRegister

No Video